Intraamniotic surfactant for prevention of neonatal respiratory distress syndrome (IRDS): rationale and personal experience

Eur J Obstet Gynecol Reprod Biol. 1997 Feb;71(2):135-9. doi: 10.1016/s0301-2115(96)02623-1.

Abstract

Objective: To evaluate the efficacy of intramniotic instillation of supplementary surfactant for the prophylaxis of neonatal IRDS in an emergency obstetric setting.

Study design: Supplementary natural surfactant (SS) was administered intra-amniotically (80 mg in 1 ml) under ultrasound guidance in the proximity of the fetal nostrils and mouth in six pregnant women at 24-32 weeks gestation, with immature amniotic fluid indices of fetal lung maturity, and whose delivery was imminent because of severe fetal distress, deteriorating maternal conditions, or refractory vaginal bleeding. The administration of SS was preceded by IV aminophylline to the mother (a bolus of 240 mg over 10 min, and a maintenance dose of 0.02-0.1 mg kg-1 min-1) in order to elicit sustained fetal breathing movements.

Results: The clinical conditions of the six newborn infants were good with no respiratory problems in four cases, and with mild IRDS in the remaining two, which, however, resolved uneventfully.

Conclusions: It is suggested that this prophylactic approach has a great potential for becoming a reliable option for the antenatal prevention of IRDS.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amnion
  • Female
  • Gestational Age
  • Humans
  • Infant, Newborn
  • Pregnancy
  • Prenatal Care / methods*
  • Respiratory Distress Syndrome, Newborn / prevention & control*
  • Surface-Active Agents / therapeutic use*
  • Treatment Outcome

Substances

  • Surface-Active Agents